Massachusetts is currently home to 3159 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Early Foley Catheter Removal After Diverticular Colovesical Fistula Repair
NCT05235204
Recruiting
Patients undergoing surgical repair of colovesical fistula will have have "early" (post-operative day 3) cystogram and removal of bladder catheter. Outcomes from the "early" group will be compared to historical "late" group data to determine if early bladder catheter removal is safe.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: UMass Memorial Medical Center Memorial Campus, Worcester, Massachusetts
Conditions: Colovesical Fistula
Register for Updates
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
PACE CF, a 3-session Mind-body Pain Management Program for Adults with Cystic Fibrosis
NCT06606457
Recruiting
Many people living with cystic fibrosis (CF) experience pain. However, pain is sometimes unrecognized and under-managed in people with CF. Both medication and non-medication interventions can be used to treat pain and ideally, there is a multicomponent management approach. The goal of this study is to pilot a new 3-session non-medication mind-body pain management intervention specifically designed for adults with cystic fibrosis (CF). The intervention is titled Pain Acknowledgement Coping and E... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis (CF), Pain Management
Register for Updates
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed/Refractory Non-Hodgkin Lymphoma
Register for Updates
Long-term Follow-up of Subjects Treated with CAR T Cells
NCT05024175
Recruiting
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Boston Birth Cohort Study
NCT03228875
Recruiting
Early life exposures may lead to adverse effects on health in later life. The Boston birth Cohort study is designed to study a broad array of early life factors and their effects on maternal and child health outcomes.
Gender:
ALL
Ages:
Between 0 years and 50 years
Trial Updated:
09/18/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Pregnancy Complications, Maternal Health, Child Health, Birth Outcome, Adverse
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Neuroblastoma
Register for Updates
tRNS Treatment for ADHD Symptoms
NCT06189703
Recruiting
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.
Gender:
ALL
Ages:
Between 7 years and 12 years
Trial Updated:
09/17/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: ADHD
Register for Updates
Phase 2 Study of EDG-5506 in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy (FOX)
NCT06100887
Recruiting
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Gender:
MALE
Ages:
Between 6 years and 17 years
Trial Updated:
09/17/2024
Locations: University of Massachusetts Memorial Medical Center, Worcester, Massachusetts
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
NCT04561206
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed Classic Hodgkin Lymphoma
Register for Updates
Abemaciclib and Endocrine Therapy in Older Patients with Breast Cancer.
NCT04305834
Recruiting
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
09/17/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates